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Statistics clearly show an unmet need for highly eﬀective contraception, especially in less developed countries. Many of these
countries are at the core of the HIV/AIDS epidemic and show very high prevalence rates for other sexually transmitted infections
(STIs) such as that caused by HSV-2. A woman at risk of unintended pregnancy due to unprotected intercourse is also at risk
for HIV/STI. Owing to their causative interrelationship, combining protection against these conditions will result in enhanced
prevention and health beneﬁts. Existing multipurpose prevention modalities such as condoms and physical barriers, albeit
eﬃcacious, face cultural hurdles that have so far hindered their widespread use. Success has recently been demonstrated in large
clinical trials, demonstrating proof of concept of microbicides in reducing the incidence of HIV-1 and HSV-2 among at-risk
populations.Thechallengeheretoforeistoreﬁnetheseproductstomakethemmorepotent,convenient,accessible,andacceptable.
Potent antiviral drugs released topically in the female reproductive tract by innovative delivered systems and formulations will
provide safe, eﬀective, and acceptable multipurpose prevention tools. This paper provides an overview of existing and novel
approaches to multipurpose prevention strategies.
1.SigniﬁcantNeedfor Innovative,
Effective,and Acceptable Multipurpose
Prevention Technologies
Eﬀective multipurpose prevention technologies (MPTs) for
women’s reproductive health is an area searching for inno-
vative strategies and approaches to increase access and
adherence [1]. Here, we will discuss technologies designed to
preventpregnancyandsexuallytransmittedinfections(STIs)
and combinations of antiviral drugs to provide synergistic
prophylaxis against multiple STIs. Unintended or mistimed
pregnancies and STIs are prevalent and morbid problems
worldwide. Although distinct issues with varying causes, the
same behavior, unprotected intercourse, puts a woman at
risk for both problems. Therefore, prevention of two or
moreoftheseconditionscouldpotentiallybetargetedbyone
multipurpose product.
2.UnintendedorMistimed Pregnancies:
A SigniﬁcantProblem Worldwide
Almost half of all pregnancies worldwide, estimated to be
over 100 million annually, are unintended or mistimed [2,
3]. In 2008, this resulted in 43 million abortions, half of
which were performed under unsafe conditions, leading to
almost 100,000 maternal deaths and 5 million women left
with temporary or permanent disabilities [3]. Despite the
existence of a variety of eﬀective contraceptives available
worldwide,discontinuationornonuseremainshigh,primar-
ily due to cost, side eﬀects, inconvenient dosing schedules,
pooraccesstoprescriptionproducts,and/orpooracceptance
of the method. This results in an unacceptably high rate of
unintended or mistimed pregnancies. Statistics clearly show
an unmet need for highly eﬀective contraception, especially
in less developed countries, where 99% of maternal deaths
occur [2, 3].2 Infectious Diseases in Obstetrics and Gynecology
3. The HumanImmunodeﬁciency VirusType1
(HIV-1)Pandemic
Less developed countries, especially those of sub-Saharan
Africa and south Asia, are also at the core of the acquired
immunodeﬁciency syndrome (AIDS) epidemic. Over 33
million people worldwide are infected with human immun-
odeﬁciency virus type 1 (HIV-1) and 22.4 million, the
majority of whom are women, live in sub-Saharan Africa
[4]. Although progress has been made in preventing new
HIV-1 infections, AIDS-related illnesses remain a leading
cause of death globally [5]. In 2008, some communities in
the USA, including pockets of the District of Columbia, had
HIV-1 incidence rates similar to that of sub-Saharan Africa
[6].
4. Impact of Lower GenitalTract Infections
on HIV-1 Acquisition
Despite a global pandemic, it is estimated that approximately
99% ofunprotected vaginal exposures to HIV-1do not result
in a productive infection [7]. This is in part due to the
formidable protection aﬀorded by an intact, healthy cervico-
vaginal epithelium. Three lower genital tract infections have
been highly associated with an increased susceptibility to
HIV-1 infection, even after controlling for other high-risk
sexual behaviors [8–10]. Speciﬁcally, they are Trichomonas
vaginalis (TV) [11, 12], bacterial vaginosis (BV) [13–17],
and herpes simplex virus type 2 (HSV-2) [18–20]. These
infections are all highly prevalent, not reportable, frequently
recurrent, and often asymptomatic. These attributes repre-
sent a perfect storm for perpetuating the spread of HIV-1.
Sexual transmission of HIV-1, in the absence of cofactors,
is poorly eﬃcient. Lower genital tract infections enhance
HIV-1 acquisition through the cervicovaginal mucosa by
inducing a proinﬂammatory state, weakening the integrity
of the epithelial barrier, and/or decreasing local innate
immunity and normal epithelial defenses, in addition to
disrupting the protective eﬀects of the normal, lactobacilli-
dominated vaginal microbiome [21]. This is why MPT
products which protect against HIV-1 and lower genital
tract infections which function as HIV-1 susceptibility
cofactors are likely to have a synergistic eﬀect in stemming
the epidemic.
5. Rationale for Multipurpose Prevention
Technologies (MPTs)
MPTs oﬀer solutions to more than one reproductive need.
This translates into several beneﬁts for the users such
as improved convenience, adherence, eﬀectiveness, cost-
reduction, and environmental impact. For the most part,
existing MPTs, for example, male condoms, have been
proven to be eﬀective against unintended pregnancies and
STIs [22, 23]. However, prevalence of use is generally low
due to acceptance and compliance issues [24]. New MPTs
should be more eﬀective and less user dependent, not
interfere with sexual pleasure, and provide additional health
beneﬁts.
6. ExistingMPTs andImprovedDerivatives
6.1. Male and Female Condoms. MPT barrier methods
include the male and female condom, diaphragms, and
cervical caps. The cornerstone MPT is the male condom.
This established product provides highly eﬀective protection
from pregnancy [22]a n dH I V - 1[ 23], when used correctly.
Low cost and worldwide over-the-counter availability are
additional desirable features of the male condom. The main
obstacle to using the male condom as an eﬀective MPT,
however, is reﬂected in the disparity between the theoretical
failure rates (2-3%) versus typical failure rates at one year of
use (approximately 15%), indicating that this method suﬀers
from inconsistent and improper use, mainly due to accept-
ability issues [24]. Many women cannot negotiate condom
use with their male partner, as this could imply distrust in
the relationship, so many experts advocate considering other
options for MPT [25]. Health and community education has
been a main format of increasing acceptance of condoms,
particularly by men [25]. Access to free male condoms has
reduced the incidence of STIs in targeted populations, such
asmilitarymembers[26].Otherstrategiessuchasadvocating
for reduced pricing of condoms or distributing free condom
packsatnightclubsfrequentedbyat-riskgroups,suchasmen
who have sex with men, have also been undertaken to reduce
the spread of STIs [27].
The female condom (FC) has been advocated as a means
for a female controlled physical barrier method to prevent
pregnancy and STIs. Female condoms, like male condoms,
prevent semen from reaching the cervix and vagina. The
contraceptive eﬃcacy of female condoms has been shown to
be comparable to or even slightly higher than male condoms
[28, 29]. The female condom performed as well as the
male condom in reducing the recurrence of bacterial STIs
[30]. Although there are no formal HIV-1 prevention trials
with the female condom, mathematical models predict an
eﬀectiveness of 63–82% [31, 32]. The ﬁrst female condom
or FC1 was approved by the United States (US) Food
and Drug Administration (FDA) in 1993. It is made of
polyurethaneandmarketedundermanytradenamesinclud-
ing the Reality female condom or the FC1 female condom
[33, 34]. However, the polyurethane made a distracting
crinkling noise with intercourse and was more expensive
than the FC2, a newer female condom, manufactured by
the Female Health Company, which is made of a synthetic
latex (nitrile) [34]. The cost of the FC2 remains higher
than that of a male condom. In an eﬀort to further reduce
costs and improve acceptability, organizations such as the
World Health Organization (WHO) have investigated the
performance of the FC2 using an in vitro design, after
subjecting the condoms to multiple rounds of washing,
disinfecting, drying, and relubrication, and found that the
integrity of the condoms remained high [35]. Although the
FC2 is currently recommended for single use, epidemiologic
studies show the FC2 to have comparable cost-eﬀectiveness
to the male condom, especially when widely distributed
to at-risk populations as a method to decrease HIV-1
transmission [32]. The FC1 and FC2 condoms are shown in
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Figure 1: Design of the FC1 and the FC2.
Figure 2: PATH Woman’s Condom.
In an eﬀort to increase acceptance and use of the female
condom, the Program for Appropriate Technology in Health
(PATH) has produced a novel FC product, the contraceptive
eﬃcacy of which is currently being tested in an NICHD-
funded multicenter trial. A subset study, conducted by
CONRAD, will look at biomarkers of semen exposure in
the female vagina, before and after product use. The PATH
Woman’s Condom (WC) performed well in a short-term
acceptabilitystudyandinacomparativecrossoverstudywith
the FC1 [36, 37]. The WC has a pliable polyurethane pouch,
a soft outer ring, and 4 elliptical foam pieces on the outside
of the pouch that cling to the vagina to stabilize the device.
The distal end of the pouch and foam pieces are packaged in
a capsule that serves as an insertion aid and dissolves quickly
afterinsertion(Figure2).Thisdesignchangewasputinplace
to increase acceptability of the WC.
6.2. Female Diaphragms. The cervix has a higher density of
CD4 cells and CCR5 chemokine receptors than the vagina
[38]. It has also been identiﬁed as an initial site of SIV
infection in macaque experiments [39]. These and other
lines of evidence suggest that the endocervix is a primary
infection site for HIV-1 and other STIs [40]. Several groups
have tried to employ diaphragms as MPTs. Diaphragms
have traditionally been used for contraception and oﬀer
similar failure rates as male condoms [41]. Cross-sectional
studies and case control studies showed that acquisition of
Neisseria gonorrhoeae (GC) and Chlamydia trachomatis (CT)
isloweramongwomenwhochoosediaphragmsthanwomen
who choose other nonbarrier methods of contraception [42,
43]r e v i e w e di n[ 44]. Based on these observational data,
the Methods for Improving Reproductive Health in Africa
or MIRA trial was launched to compare the eﬃcacy of
the Ortho All-Flex diaphragm, lubricant gel (Replens) and
condoms to condoms alone in preventing HIV-1, GC, and
CT in at-risk women [45, 46]. In these large trials, there
was no statistically signiﬁcant diﬀerence in the incidence of
HIV-1 [45] or GC and CT [46] among the two cohorts.
However, the proportion of women using condoms in the
diaphragm plus condom group was signiﬁcantly lower than
the condom alone group (54% versus 85%, P<0.001),
suggesting that the diaphragm plus lubricant provided at
least as eﬀective protection against HIV-1, GC, and CT as
condoms alone, although these studies were not designed to
test a noninferiority hypothesis [45, 46].
A disadvantage of traditional female diaphragms is that
they require ﬁtting by a health care professional and are
therefore available by prescription only in many countries.
PATH,incollaborationwithCONRAD,developedandtested
the SILCS diaphragm, a new, single size (one size ﬁts most)
contraceptive diaphragm designed to oﬀer easier insertion
and removal, increased comfort, elimination of latex-related
odors and allergic reactions, and greater durability than latex
diaphragms.TheSILCSdiaphragmismadeofsilicone,which
is sturdy and more tolerant of extreme storage temperatures.
It has a polymer material spring, which is less expensive and
easier to assemble than metal springs, which are used in
several latex diaphragms. The SILCS diaphragm performed
w e l li np h a s eIp o s t c o i t a lb a r r i e re ﬀectiveness testing,
performed in the USA [47]. Data also showed that couples in
lowresourcesettingspreferredtheSILCSdiaphragmoverthe
Ortho All-Flex diaphragm in a comparative cross-over study
[48]. CONRAD studied the clinical eﬃcacy of the SILCS
diaphragm with BuﬀerGel, from 2008 to 2009 in a USAID-
funded study. The data from this study are in analysis, and
FDA approval of this device could be as early as this year.
The SILCS diaphragm (shown in Figure 3) is currently also
being considered as a delivery system for tenofovir 1% gel
and other candidate microbicides.
6.3. Chemical Barriers (Contraceptive Microbicides). Sper-
micides are the mainstay of contraceptive chemical barrier
methods. In the USA, the only FDA-approved spermicide
available, which is widely used as a condom lubricant or
in vaginally inserted foams, gels, and ﬁlms, is nonoxynol-
9 (N9). N9 is a surfactant that immobilizes or kills sperm4 Infectious Diseases in Obstetrics and Gynecology
Figure 3: The SILCS diaphragm.
by disrupting the lipid membrane. Early in the development
of dual technology products, N9 and C31G (also known
as SAVVY, developed by BioSyn, Inc.), both surfactants,
were found to inhibit HIV-1 cell entry in vitro [49–53].
However, the in vitro and early preclinical and clinical data
did not translate into eﬀective, large-scale in vivo prevention
methods, with some data indicating that frequent use of
surfactants increased the susceptibility of the female genital
tract to HIV-1, likely due to subclinical inﬂammation caused
by these detergents [54–56].
The second generation of chemical barriers as MPTs
was large, polyanionic sulfated, or sulfonated polymers that
targeted the positively charged regions of the viral envelope
of HIV-1 and/or blocked attachment, fusion or entry of the
virus into host cells. These compounds included cellulose
sulfate (CS or Ushercell, developed by TOPCAD/CONRAD),
Carrageenan (also known as Carraguard and PC-515, devel-
opedbythePopulationCouncil),andPRO2000(alsoknown
as PRO 2000/5, developed by Indevus Pharmaceuticals).
Ushercell also showed contraceptive properties equivalent to
that of N9, in a noncomparative clinical trial where a 6%
CS gel was used by 200 couples as their sole contraceptive
method [57]. Although in vitro and early clinical data were
promising for all these diﬀerent HIV-1 entry inhibitors,
large-scale prevention trials showed no increased protection
over placebo [58–61].
Finally, products which worked to maintain the normal
acidic pH of the vagina were introduced as potential MPTs.
It was hypothesized that these products would maintain the
healthy vaginal pH in the presence of semen and would
work to partially inactivate pathogens that are acid sensitive,
including HIV-1. Unfortunately, BuﬀerGel (developed by
ReProtect LLC) was found to have no signiﬁcant protective
eﬀect for HIV-1 [62]. However, it was shown to be safe and
spermicidal [63]. Table 1 summarizes recent MPT clinical
trials.
Although research and development of dual contracep-
tive microbicides has yet to produce a safe and eﬀective
product, researchers continue to discover new approaches
to achieve this goal. Examples of these eﬀorts include
dermaseptins, magainins and other antimicrobial peptides
[68–71], AZT derivatives [72], cellulose conjugates [73], and
other new dual action compounds [68].
7. InnovativeMPTs on the Horizon
Results from the randomized, double-blind, placebo-
controlled Centre for the AIDS Program of Research in
South Africa (CAPRISA) 004 trial, demonstrating that 1%
tenofovir vaginal gel reduced the incidence of HIV-1 by 39%
overall and also reduced the incidence of primary HSV-2
infection by 51%, provided proof that potent antiretroviral
agents could prevent HIV-1 and other prevalent HIV-1 sus-
ceptibility cofactors like HSV-2 [74]. Although a resounding
proof-of-concept, the observed 39% protection certainly
leaves room for improvement. Reduced user-dependence,
more convenient dosing, and increased potency are some of
the goals for improving future MPTs.
7.1. Innovative Dosage Forms for Intravaginal Delivery of
Tenofovir for the Prevention of HIV-1 and HSV1/2 Sexual
Transmission. Adherence is a prime concern in large preven-
tion trials. Although all users of tenofovir gel experienced
a signiﬁcant protection against HIV-1 acquisition in the
CAPRISA 004 trial, protection was related to adherence.
Speciﬁcally, high (>80% of sexual acts protected by micro-
bicide use), intermediate (50–80% of sexual acts used
microbicide), and low adherence (<50% of sexual acts
associated with microbicide use) users had a 54%, 38%, and
28% reduction in HIV-1 incidence, respectively, compared
to placebo users [74]. To increase adherence, CONRAD is
currentlydevelopinganintravaginalringcapableofreleasing
tenofovir in amounts that generate tissue concentrations
similar to those attained by the 1% gel in a rabbit phar-
macokinetic (PK) study. Designed in collaboration with Dr.
Kiser (University of Utah), the tenofovir ring is made of
hydrophilic polyurethane loaded with more than 1 gram
of tenofovir, with a daily release rate of at least 10mg/d
for a target 90-day duration. The ring has approximate
dimensions of 55mm outer diameter and 5.5mm cross-
sectional diameter, only slightly larger than the commercially
availablecontraceptiveNuvaRing.Phase1 clinicalevaluation
of the tenofovir ring is expected to initiate in early 2012.
Other intravaginal dosage forms for TFV are a fast-
dissolve ﬁlm and a fast-dissolve tablet. The TFV fast dissolve
ﬁlm, under development at the University of Pittsburgh
and Magee-Womens Research Institute, is also small and is
expected to provide similar tissue concentrations of TFV
as compared to the TFV gel given its concentrated TFV
dose. The tablet is under development by CONRAD with
an estimated phase I trial in 2012. Unlike the gel dosage
form, use of a vaginal applicator is not required for the ﬁlm
or the tablet and multiple doses may be packaged together
in compact containers, thereby making them attractive
dosage forms based on increased portability and potentially
lowering manufacturing costs and environmental impact.
7.2. Enhanced Protection against HSV/HIV Genital Infection.
Multiple lines of evidence indicate that HSV-2 infection is a
signiﬁcant HIV-1 susceptibility cofactor and that HSV-2 and
HIV-1 have potential negative impacts on both infections
[18, 19, 75–78]. However, despite the strong epidemiologicInfectious Diseases in Obstetrics and Gynecology 5
Table 1: Contraceptive and microbicide data on multipurpose prevention technologies.
Product/developer (common
brands)
In vivo human
contraceptive data
In vivo human microbicide data
Supportive Supportive Non-
supportive/Inconclusive
Physical barriers
Male condom/several
√
[22]
√
[23]
Female condom/several (FC1,
FC2, PATH Women’s Condom)
√
[28, 29]
√
[30–32]
Female diaphragm/several
(Ortho All Flex)
√
[41]
√
[45, 46]
SILCS diaphragm/CONRAD Data in Analysis Not studied
chemical Barriers: surfactants
Nonoxynol-9/several
√√
[55]
C31G/BioSyn (SAVVY)
√
[64]
√
[54, 56]
Chemical barriers: attachment, entry and fusion inhibitors: (polyanionic sulfated or sulfonated polymers)
Cellulose Sulfate (Ushercell,
CS)/Polydex Pharmaceuticals,
Program for the Topical
Prevention of Conception and
Disease (Rush University),
CONRAD
√
[57]
√
[58, 61]
Carrageenan/Population Council
(Carraguard, PC-515)
√
[59]
PRO2000/Indevus
Pharmaceutical (PRO2000/5)
In vitro,n ol a r g e
human studies
√
[60, 62]
Acid buﬀers and vaginal defense enhancers
BuﬀerGel/ReProtect LLC
√
[65]
√
[62]
Acidform Gel (Amphora)
Instead Sciences
√
[66, 67] No large human eﬃcacy trials
and observational data linking these two infections, ran-
domized controlled trials using prophylactic oral acyclovir
(ACV) in HSV-2-positive individuals to reduce the incidence
of HIV-1 have not shown a signiﬁcant preventative eﬀect
[79, 80]. In addition, ACV prophylaxis in HSV-2 and HIV-
1 seropositive individuals did not reduce transmission of
H I V - 1t os e r o n e g a t i v es e x u a lp a r t n e r s[ 81]. The potential
reasons for failure of the interventional trials are several but
include persistence of inﬂammatory inﬁltrates, compliance
with prophylactic therapy, and adequate delivery of antiviral
medications to genital tissues.
Frank disruption of the genital epithelium by HSV-
2 lesions is likely not the only mechanism by which the
genital mucosa becomes more susceptible to HIV-1 infection
[21]. The surrounding epithelium has subclinical changes
in inﬂammatory and innate immune response, including an
inﬂux of CD4+ and CD8+ cells, which persist for months
even after an epithelial lesion has healed, leaving apparently
normal genital epithelium still vulnerable to HIV-1 infection
[82, 83]. Oral ACV therapy does not alter the persistence of
these HIV-1 target cells [82, 83].
Compliance with prophylactic therapy was assessed by
participantreportandpillcounting[80]andwithserumand
urine ACV levels [79]. PK data indicated that compliance
with daily oral therapy was poor in one trial [79]. It is likely
that compliance with preventative treatment would increase
with a more convenient and long acting dosing regimen
such as an intravaginal ring. It is known that plasma and
vaginal levels of ACV are poorly correlated (r = 0.28, P>
0.05), with vaginal secretions containing 15–170% (mean
79%) of plasma ACV levels [84, 85]. PK studies demonstrate
that peak vaginal concentrations of ACV are reached 30–60
minutes after oral dosing [85]. Peak vaginal concentrations
of ACV (0.8–3.6nmols/g or 0.18–0.81µg/mL) after daily oral
dosing have also been shown to be below the 50% inhibitory
dose of ACV for HSV-2 (approximately 0.91µg/mL) [86].
These data suggest that higher oral doses of ACV would
be required to prevent primary infection by HSV-2 or to
reduce recurrent genital epithelial replication and shedding.
Inaddition,misseddosesoforalACVmaysigniﬁcantlyaﬀect
adequate genital concentrations of the drug.
This is why we have begun to develop a tenofovir and
ACV combination vaginal product. We believe that the
eﬃcacy of tenofovir in preventing primary HSV-2 infections,
shown in the CAPRISA 004 study [74], may be improved
signiﬁcantly by adding topical delivery of ACV. We also
hypothesize that increasing the concentration of tenofovir
in the genital tissues will increase its eﬀectiveness. These6 Infectious Diseases in Obstetrics and Gynecology
hypotheses are supported by data from the CAPRISA-
004 trial, which directly correlated the concentrations of
tenofovir and its active metabolite tenofovir diphosphate,
in genital tract secretions and tissues with the likelihood of
preventing HIV-1 or HSV-2 [87]. Tenofovir and ACV will
be synergistic in an MPT product to prevent HIV-1 and
HSV-2. We hypothesize that ACV, delivered topically and
vaginally, will result in higher local tissue concentrations,
which would reduce or control HSV-2 epithelial replication
and the subclinical changes in the genital mucosa associated
with recurrent HSV-2 outbreaks.
CONRAD is currently developing an intravaginal ring
for the sustained dual delivery of tenofovir and ACV.
Tenofovir and ACV have similar hydrophilicity and therefore
may be suitably coformulated in hydrophilic polyurethanes.
In collaboration with Controlled Therapeutics (East Kil-
bride, Scotland), a 10% tenofovir/10% ACV hydrophilic
polyurethane ring with dimensions similar to NuvaRing was
developed that is capable of releasing milligram quantities
of each drug daily for up to one month. Ongoing product
development eﬀorts continue to increase these release rates
as well as extend the duration of drug release.
Another intravaginal ring design well suited for use as a
sustained MPT dosage form, and particularly for codelivery
of tenofovir and ACV, is the drug pod-based Versaring
technology currently being developed by Auritec and Oak
Crest Research Institute (Pasadena, Calif). This technology
uses a silicone elastomer ring as primarily a physical holder
for ten individually formulated—and subsequently inde-
pendently rate-controlled—drug cores or pods (∼3–20mg
drug per pod) that provides remarkably controlled release
proﬁles. With CONRAD’s collaboration, a tenofovir/ACV
combination intravaginal ring using this technology is also
currently under development.
Although randomized controlled trials of Carraguard
failed to demonstrate eﬃcacy in preventing HIV-1 infection
[59], it was found to be safe, well tolerated, and physically
s t a b l e .T h e s ep r o p e r t i e sm a k ec a r r a g e e n a nag o o dd e l i v e r y
vehicle for other microbicide candidates. Furthermore, it
has demonstrated high anti-HPV activity in vitro [88].
The Population Council commenced early preclinical and
animal testing of a combination MIV-150, a nonnucleoside
reversetranscriptaseinhibitordevelopedbyMedivirandzinc
acetate,preparedinadeliveryvehicleofcarrageenangel[89],
named PC 1005. This MPT showed complete protection
against RT-SHIV infection for up to 8 hours after daily
d o s i n gf o r1 4d a y s[ 89]. In vitro data suggest that zinc salts
have activity against HIV-1 [90]a n dH S V - 2[ 91, 92].
7.3. Innovative MPT for the Prevention of HIV-1 Acquisition
and Unintended Pregnancies. Although the recent news
of tenofovir as an anti-HIV-1 microbicide is compelling,
tenofovir is not a contraceptive. To solve this problem, we
are also currently developing an MPT with extended dosing
of levonorgestrel (LNG) and tenofovir in an intravaginal
ring which would be eﬀective for at least 90 days (Figure 4).
We chose LNG because of its long track record of safety
and eﬃcacy [93, 94]. The WHO previously developed a
Figure 4: Segmented intravaginal ring for codelivery of tenofovir
(long white segment) and levonorgestrel (short segment). Photo
courtesy of Dr. Patrick Kiser (University of Utah).
microdose LNG eluting silicone vaginal ring as a one-year
contraceptive product, which went through extensive safety,
eﬃcacy, and acceptability testing. The product was not
pursued at the time, however, due to funding considerations
[95–97].
The tenofovir/LNG intravaginal ring under development
in collaboration with the University of Utah builds on both
the millidose tenofovir vaginal ring described above and
WHO’s work on the microdose LNG ring. One of the major
challenges to developing a combination ring for these two
particular drugs is the large (three orders of magnitude)
diﬀerence in target release rates between tenofovir and LNG.
Moreover, LNG’s hydrophobicity lends itself to formulation
in, and delivery from, hydrophobic polymers. The design
of our ring overcomes both of these challenges by for-
mulating the drugs separately in two independent drug-
loaded segments, with the tenofovir segment comprising
more than 80% of the ring’s total volume (maintaining the
ring’s capacity to deliver 10mg/d tenofovir) and the short
LNG segment formulated with hydrophobic polyurethanes
for delivery of 20µg/d LNG. Dr. Kiser’s group has previously
reportedontwo-segmentpolyurethaneintravaginalringsfor
thecodeliveryoftenofoviranddapivirine[98].Phase2bdose
and safety testing of this product is expected to begin in the
next year.
In collaboration with PATH (Program for Appropriate
Technology in Health), CONRAD is also testing the delivery
of TFV gel by SILCS, a one-size-ﬁts-all diaphragm with
contraceptive barrier properties. This combination should
provide coitally associated contraception and prevention of
HIV-1 and HSV-2 acquisition.
The International Partnership for Microbicides (IPM)
has developed an intravaginal ring which elutes dapivirine
(TMC120), a nonnucleoside reverse transcriptase inhibitor
(NNRTI), for one month [99–101]. Dapivirine has been
shown to be eﬀective in preventing HIV-1 infection in vitro,
using cell line and tissue explant models [102]. DapivirineInfectious Diseases in Obstetrics and Gynecology 7
has been studied in phase 1 and 2 dosing and safety
studies [103, 104]. IPM has partnered with the Population
CouncilindevelopinganMPTintravaginalringwhichelutes
dapivirine and levonorgestrel, showing promise in early
laboratory and preclinical studies [105].
8. Conclusions
Multipurpose prevention technologies, MPTs, encompass
simultaneous prevention of STIs and unintended preg-
nancies as well as prevention of more than one STI or
reproductive tract infection. Established methods include
barrier devices such as male and female condoms and female
diaphragms. Innovations to these traditional MPT products
are underway to improve accessibility, acceptability, and
eﬃcacy.Althoughclinicaltrialsfailedtodemonstrateeﬃcacy
against HIV-1 transmission for the ﬁrst generations of
chemical MPT products including spermicides (nonoxynol-
9 and C31G), polyanionic sulfated or sulfonated polymers
(cellulose sulfate, carrageenan, and PRO 2000), and vaginal
pH buﬀers (BuﬀerGel), research and development continues
to optimize the contraceptive properties of some of these
compounds or to use these compounds as delivery vehicles
for more potent antivirals or spermicides. Some of them, for
instance carrageenan, are being further considered for new
applications. Proof of concept for a chemical MPT, tenofovir
vaginal gel, has just been demonstrated for the prevention of
HIV-1 and primary HSV-2 infections. Research is underway
to simplify the dosing of tenofovir vaginal gel and develop
other delivery systems for tenofovir alone or in combination
with contraceptive hormones (e.g., levonorgestrel) or other
potent antivirals.
Women at risk for unintended pregnancies are by deﬁni-
tionalsoatriskofSTIs,andwomenwhoareatriskofoneSTI
are also likely at risk of several diﬀerent STIs. Data support
that women ﬁnd MPT products desirable and acceptable
[106].Simplifyingandextendingthedosingregimen,decou-
pling prophylaxis from coital acts, and developing female
controlled protection products are all innovative strategies
and approaches to increase the use of these much needed
technologies. MPTs are likely to have a synergistic impact
on the epidemics of sexually transmitted infections and
unintended pregnancies and facilitate implementation and
uptake of these biomedical preventative interventions.
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